STAAR Surgical Q2 net sales jump on China sales growth
STAAR Surgical Q2 net sales jump on China sales growth
Overview
U.S. intraocular lens maker's Q2 net sales rose 111% yr/yr to $93.5 mln
Company swung to Q2 net income of $8.1 mln, EPS $0.16, from loss a year ago
Growth driven by strong China demand and improved gross margin
Outlook
Company expects strong ICL demand in key markets to continue through the rest of 2026
STAAR anticipates third-quarter China sales to step down from H1 peak, but still grow Y/Y excluding prior one-time order
Company expects margin pressures from tariffs to persist until all China-bound products are made in Switzerland by end-2026
Result Drivers
CHINA SALES GROWTH - Co said Q2 sales in China rose over 100% yr/yr, driven by higher procedure volume, market share gains, and a favorable product mix following the EVO+ launch
APAC AND AMERICAS CONTRIBUTION - Co said Japan and broader APAC region, as well as the Americas, contributed to growth, with Japan benefiting from direct-to-consumer campaigns and the Americas seeing market share gains as laser vision correction procedures declined
GROSS MARGIN IMPROVEMENT - Co attributed higher gross margin to elimination of period costs from manufacturing ramp-up, lower inventory provisions, and decreased freight and other costs, partially offset by higher per unit manufacturing costs and increased tariffs
Company press release: ID:nBw8LKTtWa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales |
| $93.54 mln |
|
Q2 EPS |
| $0.16 |
|
Q2 Net Income |
| $8.06 mln |
|
Q2 Gross Margin |
| 74.5% |
|
Q2 Gross Profit |
| $69.73 mln |
|
Q2 Operating Income |
| $10.10 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for STAAR Surgical Company is $29.00, about 16.3% above its August 11 closing price of $24.94
The stock recently traded at 53 times the next 12-month earnings vs. a P/E of 277 three months ago
Reuters Recommended Reads
Aug 11 - Eye care company Alcon raises margin outlook, shares jump
Aug 11 - LENZ Therapeutics Q2 revenue rises on VIZZ sales
Aug 12 - Singapore's Beverly JCG half-year revenue falls 32% on weaker aesthetic medical
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)